Leerink Swann Starts Questcor Pharmaceuticals (QCOR) at Outperform; Expecting Meaningful Acthar Growth

Article Stock Quotes (1) Comments (0)

Leerink Swann initiates coverage on Questcor Pharmaceuticals (NASDAQ: QCOR) with an Outperform. PT range $50-$53.

Analyst, Irene Lau, said, "Our valuation is driven by meaningful expected Acthar growth in nephrotic syndrome (NS), modest growth in MS, and incremental revenue from Dermato and Polymyositis (DM/PM). For MS, a solid treatment and retreatment experience among a predominantly affluent patient base should at least preserve MS revenues if almost generics arise. For NS, we see potential upside if larger clinical trials demonstrate utility in diabetic nephropathy (DN). For PM/DM, we project modest Acthar revenue with longer-term upside if lupus and rheumatoid or psoriatic arthritis demonstrates strong data."

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $44.12 yesterday, with a 52 week range of $24.14-$58.91.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
• Wedbush Downgrades salesforce.com (CRM) to Neutral
• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines

Create E-mail Alert Related Categories

New Coverage

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?